Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nurit Friedman

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
The Annals of Pharmacotherapy|December 28, 2006
Brand versus generic alendronate: gastrointestinal effects measured by resource utilizationHillel Halkin, Marina Dushenat, Barbara Silverman, et al.
Plos Genetics|August 8, 2014
The response to high CO2 levels requires the neuropeptide secretion component HID-1 to promote pumping inhibitionKfir Sharabi, Chayki Charar, Nurit Friedman, et al.
Parkinsonism & Related Disorders|November 5, 2013
Parkinson's disease patients first treated at age 75 years or older: a comparative studyChava Peretz, Orly Chillag-Talmor, Shai Linn, et al.
Journal of Parkinson'S Disease|August 14, 2013
Use of a refined drug tracer algorithm to estimate prevalence and incidence of Parkinson's disease in a large israeli populationOrly Chillag-Talmor, Nir Giladi, Shai Linn, et al.
Journal of Clinical Pharmacology|May 21, 2010
Database evaluation of the effects of long-term rosiglitazone treatment on cardiovascular outcomes in patients with type 2 diabetesRonen Loebstein, Marina Dushinat, Janet Vesterman-Landes, et al.
Frontiers in Cardiovascular Medicine|November 17, 2022
Sex related differences in the characteristics and outcomes of heart failure: A sub analysis of heart failure disease management studyAvishay Grupper, Dov Freimark, Havi Murad, et al.
BMC Medicine|May 2, 2017
Disease management in the treatment of patients with chronic heart failure who have universal access to health care: a randomized controlled trialOfra Kalter-Leibovici, Dov Freimark, Laurence S Freedman, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
The Annals of Pharmacotherapy|December 28, 2006
Brand versus generic alendronate: gastrointestinal effects measured by resource utilizationHillel Halkin, Marina Dushenat, Barbara Silverman, et al.
Plos Genetics|August 8, 2014
The response to high CO2 levels requires the neuropeptide secretion component HID-1 to promote pumping inhibitionKfir Sharabi, Chayki Charar, Nurit Friedman, et al.
Parkinsonism & Related Disorders|November 5, 2013
Parkinson's disease patients first treated at age 75 years or older: a comparative studyChava Peretz, Orly Chillag-Talmor, Shai Linn, et al.
Journal of Parkinson'S Disease|August 14, 2013
Use of a refined drug tracer algorithm to estimate prevalence and incidence of Parkinson's disease in a large israeli populationOrly Chillag-Talmor, Nir Giladi, Shai Linn, et al.
Journal of Clinical Pharmacology|May 21, 2010
Database evaluation of the effects of long-term rosiglitazone treatment on cardiovascular outcomes in patients with type 2 diabetesRonen Loebstein, Marina Dushinat, Janet Vesterman-Landes, et al.
Frontiers in Cardiovascular Medicine|November 17, 2022
Sex related differences in the characteristics and outcomes of heart failure: A sub analysis of heart failure disease management studyAvishay Grupper, Dov Freimark, Havi Murad, et al.
BMC Medicine|May 2, 2017
Disease management in the treatment of patients with chronic heart failure who have universal access to health care: a randomized controlled trialOfra Kalter-Leibovici, Dov Freimark, Laurence S Freedman, et al.
Pageof 2